Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EW stock price vs SNBR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SNBR's multiple
Needs SNBR P/E.
Implied fair value · at EW's multiple
Needs Annual EPS is negative, EW P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Edwards Lifesciences Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
SLEEP NUMBER CORPORATION · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
EW vs ABT
JOHNSON & JOHNSON
EW vs JNJ
Medtronic plc
EW vs MDT
BOSTON SCIENTIFIC CORP
EW vs BSX
BAXTER INTERNATIONAL INC
EW vs BAX
DENTSPLY SIRONA Inc.
EW vs XRAY
LEGGETT & PLATT INC
EW vs LEG
TEMPUR SEALY INTERNATIONAL, INC.
EW vs TPX
LA-Z-BOY INC
EW vs LZB
MILLERKNOLL, INC.
EW vs MLKN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EW's superior margins, growth, and capital efficiency can persist despite a valuation that looks rich versus DCF, then holding or accumulating EW is reasonable because SNBR is too distressed to serve as a clean undervalued SNBR benchmark.
The valuation gap is extreme on every standard metric: EW trades at 8.2x P/S and 47.0x P/E, while SNBR is at 0.0x P/S and effectively no positive earnings multiple because it is loss-making. The provided implied price from the P/S multiple is $0.00, which suggests the relative valuation framework is not producing a meaningful anchor here and is likely dominated by SNBR's distressed financial profile.
Supporting Metrics
